Abstracts Archive - Page 38 of 2607 - ACR Meeting Abstracts

Abstract Number: 0057 • ACR Convergence 2025
TNF Inhibition with Small-molecule Agents Results in Amelioration of Inflammation Similar to that of Anti-TNF Biologics While Preserving TNFR2 Signaling and Maintaining a Suppressive Regulatory T cell Phenotype
Rajesh Singh¹, Bindi Patel², Rameshwari Rayaji², Archana Sidalaghatta Nagaraja², Saranya Chandrasekar², Yihong Guan², Ritu Kushwaha², Yue Tong Lee², Cesar Meleza², Matthew Epplin², Brandon Rosen², Manmohan R Leleti², Matthew J Walters² and Daniel DiRenzo², ¹Arcus Biosciences, inc., Santa Clara, CA, ²Arcus Biosciences, inc., Hayward, CA
Background/Purpose: Anti-TNF biologics are effective in the treatment of inflammatory diseases such as rheumatoid arthritis and psoriasis. However, they can lead to de novo inflammation…
Abstract Number: 0021 • ACR Convergence 2025
DoCTIS: A Single Cell RNA-Seq Atlas of Drug Response To Targeted Therapies
Antonio Julià¹, Yolanda Guillén², Paloma Vela Casasempere³, Antonio Fernández Nebro⁴, Carlos Marras⁵, Santos Castañeda⁶, Jaime Calvo Alén⁷, Jesús Tornero Molina⁸, Juan Cañete⁹, Eugeni Domènech¹⁰, Javier Gisbert¹¹, Jose M. Carrascosa¹², Eduardo Fonseca¹³, Luis Bujanda Fernández De pierola¹⁴, Valle García Sánchez¹⁵, Britta Siegmund¹⁶, Giampiero Girolomoni¹⁷, Holger Heyn¹⁸, Laura Jiménez Gracia¹⁸, Pere Santamaria¹⁹, Edgar Angelats²⁰, Richard Myers²¹, Sergio H. Martínez Mateu², Juan Ángel Patiño Galindo², Ernest Choy²² and Sara Marsal¹, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²IMIDomics, Barcelona, Spain, ³Hospital General Universitario de Alicante, Rheumatology, Alicante, Spain, ⁴Hospital Regional Universitario Carlos Haya, Rheumatology, Málaga, Spain, ⁵Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Spain, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷Hospital Universitario de Araba, Rheumatology, Vitoria, Spain, ⁸Hospital Universitario de Guadalajara, Rheumatology, Guadalajara, Spain, ⁹Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁰Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, ¹¹Hospital Universitario La Princesa, Rheumatology, Madrid, Spain, ¹²Hospital Universitari Germans Trias i Pujol, Dermatology, Badalona, Spain, ¹³Complejo Hospitalario Universitario de A Coruña, Dermatology, A Coruña, Spain, ¹⁴Hospital Universitario de Donostia, Gastroenterology, San Sebastián, Spain, ¹⁵Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, ¹⁶Charité-Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany, ¹⁷University of Verona, Dermatology, Verona, Spain, ¹⁸Centre for Genomic Regulation (CNAG-CRG), Barcelona, Spain, ¹⁹Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelonoa, Spain, ²⁰Hospital Clínic-IDIBAPS, Barcelona, Spain, ²¹HudsonAlpha Institute for Biotechnology, Huntsville, AL, ²²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Targeted therapies have revolutionized the management of immune-mediated inflammatory diseases (IMIDs), however, there is a substantial number of patients who respond poorly to a…
Abstract Number: 0169 • ACR Convergence 2025
The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment
Sally Wetten¹, George Mu², Keele E. Wurst³, Roger A. Levy⁴, Ben Newth⁵, Svetlana I. Nihtyanova⁶ and Elaine Irving⁷, ¹GSK, Epidemiology, Stevenage, United Kingdom, ²GSK, Statistics, Collegeville, PA, ³GSK, Immunology and Emerging Epidemiology, Durham, NC, ⁴GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁵GSK, Specialty Care, Global Medical Affairs, London, United Kingdom, ⁶GSK, Clinical Sciences, Research & Development, London, United Kingdom, ⁷GSK, Clinical, Stevenage, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary manifestation that can occur across all connective tissue disorders (CTD). Aberrant immune-mediated inflammation and fibrosis leads…
Abstract Number: 0292 • ACR Convergence 2025
Patterns and Predictors of Longitudinal Trajectories of Pain in Individuals with Inflammatory Myopathies
Haley Zimmerman¹, Ethan Ritz², Kristin Wipfler³, Kaleb Michaud⁴ and Didem Saygin¹, ¹Rush University Medical Center, Chicago, IL, ²Rush Research Informatics Core, Rush University Medical Center, Chicago, IL, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Idiopathic inflammatory myopathies (IIM) have historically been considered a disease of painless weakness. However, recent studies indicate that most patients with IIM experience pain…
Abstract Number: 0310 • ACR Convergence 2025
Evaluate Safety, Tolerability, and Pharmacodynamics of a Single Intra-Articular Injection of GNSC-001 Gene Therapy in Subjects with Knee Osteoarthritis: 12-month Results from DONATELLO
Annahita Keravala¹, Philip Conaghan², shanna jackson¹, sharmila Vijay¹, Thomas Chalberg³, Jeyanesh Tambiah⁴ and Laurie Halligan¹, ¹Genascence, Palo Alto, CA, ²University of Leeds, Leeds, United Kingdom, ³Genascence Corp, Palo Alto, CA, ⁴Genascence, San Diego, CA
Background/Purpose: IL-1 contributes significantly to osteoarthritis (OA) pathology, driving inflammation and cartilage degradation. Prior therapies targeting IL-1 have shown limited success due to inadequate drug…
Abstract Number: 0342 • ACR Convergence 2025
Comparison of Cortical Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study
Edgar Wiebe¹, Benjamin Kuntz², Angela Galindo Santos³, Zhivana Boyadzhieva³, Sandra Hermann¹, Burkhard Muche², Andriko Palmowski², Gerhard Krönke⁴, Ralf Schmidmaier⁵, Kay Raum³ and FRANK BUTTGEREIT⁶, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁵Klinikum der Universität München, Medizinische Klinik und Poliklinik IV, München, Bayern, Germany, ⁶Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at elevated risk for osteoporotic fragility fractures. Standard assessment via dual-energy X-ray absorptiometry (DXA) does…
Abstract Number: 0315 • ACR Convergence 2025
Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.
Avanika Mahajan¹, Caroyln Harvey², Andy Abril³ and Megan Sullivan⁴, ¹Mayo Clinic, Scottsdale, ²Mayo Clinic, Phoenix, AZ, ³Mayo Clinic Florida, Jacksonville, ⁴Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Erosive hand osteoarthritis (EHOA) is an inflammatory subtype of hand OA that causes subchondral bone erosion and cortical destruction, often resulting in debilitating symptoms.…
Abstract Number: 0357 • ACR Convergence 2025
Content validation of patient-reported outcome (PRO) measures for fatigue, physical function and disease activity in Polymyositis (PM)
Jason Xenakis¹, Esther Yi¹, Iyar Mazar², Sarah Knight³, Harriet Makin³, Samantha Wratten³, Rohit Aggarwal⁴ and Stephanie McKee³, ¹Pfizer Inc., New York, United States of America, New York, ²Pfizer, US, New York, ³Clarivate, London, United Kingdom, ⁴University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Polymyositis (PM) is a subtype of idiopathic inflammatory myopathy (IIM) characterized by muscle inflammation and muscle weakness. Extra muscular manifestations like interstitial lung disease…
Abstract Number: 0374 • ACR Convergence 2025
Assessing Attitudes and Barriers to Vaccination in Pediatric Rheumatic
Merav Heshin Bekenstein¹, Rebecca Hetrick², Vidya Sivaraman³, Beth Rutstein⁴, Albert Chow⁵, Peter Chiraseveenuprapund⁶, Vincent Del Gaizo⁷, Melanie Kohlheim⁸, guy Brock⁹, Sapuni Chandrasena⁹, Chloé Janse van Rensburg¹⁰ and Marina Gad El Sayed¹¹, ¹Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ²Indiana University School of Medicine, Indianapolis, IN, ³Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ⁴The Children's Hospital of Philadelphia, Wynnewood, PA, ⁵Loma Linda University, Loma Linda, CA, ⁶University of Utah, Salt Lake City, UT, ⁷Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁸CARRA, Granville, OH, ⁹The Ohio State University Wexner Medical Center, Columbus, OH, ¹⁰Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada, ¹¹University of California, Riverside School of Medicine, Riverside, CA
Background/Purpose: Vaccine-preventable diseases pose greater risk to children with rheumatic diseases treated with immunosuppressive therapies and to those with underlying immune dysregulation. Despite the importance…
Abstract Number: 0343 • ACR Convergence 2025
Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort
Edgar Wiebe¹, Dörte Huscher², Zhivana Boyadzhieva³, Andriko Palmowski⁴, Sandra Hermann¹, Burkhard Muche⁴, Arnd Kleyer⁵, David Simon⁶, Gerhard Krönke⁷, Paula Hoff⁸ and FRANK BUTTGEREIT⁹, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Berlin, Germany, ⁸Endokrinologikum Berlin, Medizinisches Versorgungszentrum (MVZ) am Gendarmenmarkt, Berlin, Berlin, Germany, ⁹Charité University Medicine Berlin, Berlin, Berlin, Germany
Background/Purpose: Janus kinase (JAK) inhibitors are an important treatment option for rheumatoid arthritis (RA) and psoriatic arthritis (PsA). By disrupting pro-inflammatory cytokine signaling (e.g., IL-6,…
Abstract Number: 0363 • ACR Convergence 2025
Assessing Whole Health Needs in Systemic Lupus Erythematosus
Amanda Eudy¹, Megan Clowse², Dana Burshell³, Connor Drake³, Tamara Somers⁴, David Pisetsky⁵, Rebecca Sadun⁶, Ralph Snyderman⁷, Kai Sun⁶, Lisa Criscione-Schreiber³, Mithu Maheswaranathan³, Nathaniel Harris⁵, Jayanth Doss⁸ and Jennifer Rogers³, ¹Duke University, Raleigh, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University Medical Center, Durham, NC, ⁶Duke University, Durham, NC, ⁷Duke Center for Personalized Health Care, Durham, NC, ⁸Division of Rheumatology and Immunology, Duke University Department of Medicine, Durham, NC
Background/Purpose: Care models that take a ‘Whole Health’ perspective by emphasizing personalized care focused on the individual’s values, needs, and goals, rather than solely on…
Abstract Number: 0306 • ACR Convergence 2025
Direct Assessment of Intestinal Permeability as a Risk Factor for Multiple Joint Osteoarthritis in Community Cohorts of Humans and Pet Dogs
Liubov Arbeeva¹, Virginia Kraus², Richard Loeser³, Yvonne Golightly⁴, Hiroko Enomoto⁵, Masataka Enomoto⁵, Duncan Lascelles⁵ and Amanda Nelson⁶, ¹University of North Carolina, Chapel Hill, Carrboro, NC, ²Duke University, Durham, NC, ³University of North Carolina, Chapel Hill, NC, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵North Carolina State University, Raleigh, NC, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Increased intestinal permeability (IP) is common in chronic inflammatory diseases, and can be measured indirectly (e.g., with blood markers such as lipopolysaccharide, LPS), or…
Abstract Number: 0392 • ACR Convergence 2025
Clinical Indicators of Methotrexate Response in Juvenile Idiopathic Arthritis (JIA) and JIA with Uveitis (JIA-U)
Abigale Jagger¹, Mara Becker², Susan Thompson³, Mekibib Altaye⁴, John Bohnsack⁵, Hermine Brunner⁶, Margaret Chang⁷, Ashley Cooper⁸, Stefanie Davidson⁹, Alexandra Duell⁶, Bharti Gangwani⁷, Carl Langefeld¹⁰, Melissa Lerman¹¹, Mindy Lo⁷, Serena Pastore¹², Mariia Pavlenko¹³, Sampath Prahalad¹⁴, Megan Quinlan-Waters¹⁵, Laura Ramsey¹⁶, Grant Schulert⁶, Gabriele Simonini¹⁷, Erin Stahl⁸, Gabriele Stocco¹⁸, Marc Sudman¹⁹, Andrea Taddio¹⁸, Virginia Miraldi Utz⁶, Rae Yeung²⁰ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, ³Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, BLUE ASH, OH, ⁴Cincinnati Children's Hospital, Cincinnati, ⁵University of Utah, Salt Lake City, UT, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Boston Children's Hospital, Boston, MA, ⁸Children's Mercy Kansas City, Kansas City, MO, ⁹University of Pennsylvania/CHOP, Philadelphia, PA, ¹⁰Wake Forest University School of Medicine, Winston Salem, NC, ¹¹Children's Hospital of Philadelphia, Philadelphia, PA, ¹²Institute of Child and Maternal Health - IRCCS "Burlo Garofolo", Trieste, Italy, ¹³Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ¹⁴Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁵Cincinnati Children's Hospital Medical Center, CCHMC, ¹⁶Children's Mercy, Kansas City, MO, ¹⁷Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ¹⁸Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, ¹⁹Cincinnati Children's Hospital Medical Center, Cincinnati, ²⁰The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with JIA are at high risk for development of chronic anterior uveitis (CAU), impacting 10-20% of this population. Although methotrexate (MTX) is the…
Abstract Number: 0290 • ACR Convergence 2025
Comparison of Organ Damage and Survival in Anti-synthetase Syndrome and Other Idiopathic Inflammatory Myopathies: An Analysis of Patients from Turkey
Ezgi Sahin¹, Omer Uludag², yasemin yalcinkaya³, Bahar Artim Esen⁴, Ahmet Gul³ and Murat Inanc³, ¹Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul University, Istanbul Faculty of Medicine, Division of Rheumatology, Istanbul, Istanbul, Turkey, ⁴Istanbul University, Istanbul, Istanbul, Turkey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare autoimmune diseases characterized by muscle weakness, often involving other organs such as the skin, lungs, and heart. Defined…
Abstract Number: 0433 • ACR Convergence 2025
In-hospital outcomes of patients admitted due to First-Time Pulmonary Embolism with preexisting Rheumatoid Arthritis: A Nationwide Analysis 2016-2022
John Langley¹, Karuna Bista², Clarisse Yapp², Nisha Sapkota³, Shukranta Shrestha² and Sulav Pyakurel¹, ¹Montefiore New Rochelle Hospital, New Rochelle, NY, ²Montefiore New Rochelle Hospital, New Rochelle, ³Interfaith Medical Center, One Brooklyn Health, Brooklyn, NY
Background/Purpose: Although it has been documented that patients with Rheumatoid Arthritis may be at increased risk of Pulmonary Embolism, other inpatient outcomes remain largely unexplored.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].